Mattel Inc (MAT) Stock Price Today
Aura AI Summary
Key Stats
- $3.79BMarket Cap
- 8,818,227Volume
- Consumer CyclicalSector
- $22.1652W High
- $13.0552W Low
- 103 DaysTypical Hold Time
- $6.01BEnterprise Value
- -Div Yield
- 0% Sell | 100% BuyTrading Activity
Track Mattel Inc (MAT) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Mattel Inc has traded between a low of $13.05 and a high of $22.16, highlighting its annual price range. Buy and sell Mattel Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Most Recent News
Equitable Holdings directors sell shares amid mixed institutional holdings changes
Two directors of Equitable Holdings sold shares recently, with Bertram L. Scott selling 2,780 shares and Craig C. MacKay selling 2,000 shares. Meanwhile, institutional investors showed mixed activity: Engineers Gate Manager LP drastically cut its hol...

Greenland mining and chip ETFs soar on new security deal and AI optimism
Shares of Greenland-linked mining companies surged following a new U.S.-Denmark-Greenland security agreement that boosted investor interest in Greenland's mineral resources. Greenland Mines Ltd. jumped over 229%, while Critical Metals Corp. rose near...

Biotech stocks and leveraged ETFs lead market declines amid volatile trading and clinical news.
Biotech stocks and leveraged ETFs were the biggest losers in the market, with Cue Biopharma dropping 23.7% despite positive Phase 2 clinical results. Leveraged ETFs tied to AMD, Strategy, and Novo Nordisk also saw sharp declines due to their daily-re...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.